As the health insurance coverage is strengthened as social insurance, value judgment becomes a very important policy task for the efficiency of payment and payment. Among them, the weight of medicines has changed along with the coverage.

In the past, under the negative list system, the value of drug insurance was focused on listing more drugs so that people could not be treated. Naturally, the industry has focused on product licensing, which plays a decisive role in the market, and it is true that insurance was heavily influenced by the permit situation at the time.

However, weights shifted quickly as insurance policies changed with the position list. Even generics have raised the questio